April 26, 2021 -- The Carlyle Group will acquire life science tools company Unchained Labs for $435 million. The transaction is expected to close in the second quarter of 2021.
Unchained Labs develops tools used by biopharmaceutical researchers to analyze and characterize large, complex molecules. The company has 170 employees and expects to generate over $75 million in revenue in 2021.
The investment in Unchained Labs, in partnership with Novo Holdings, Canaan Partners, and TPG Biotech, marks Carlyle's commitment to healthcare in which it has invested over $16 billion of equity.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
